Vimarsana
Biggest News Aggregation in the World

Page 9 - Allogeneic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Allogeneic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Allogeneic Today - Breaking & Trending Today

Caribou Biosciences : Regulation FD Presentation - Form 8-K - Vimarsana News

Caribou Biosciences : Regulation FD Presentation - Form 8-K

Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or... | March 29, 2023

Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference - Vimarsana News

Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference

Precision BioSciences, Inc. a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will... | March 27, 2023

AlloVir Appoints Derek Adams, Ph.D., to Board of Directors - Vimarsana News

AlloVir Appoints Derek Adams, Ph.D., to Board of Directors

AlloVir , a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Derek Adams, Ph.D., to its Board of Directors, effective March 1, 2023. Dr. Adams brings... | February 23, 2023

Theriva Biologics, Inc.: Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - Vimarsana News

Theriva Biologics, Inc.: Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

- Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR - - Analysis of patients receiving meropenem suggest that SYN-004 is well-tolerated with

Atara Biotherapeutics, Inc.: Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO (tabelecleucel) - Vimarsana News

Atara Biotherapeutics, Inc.: Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO (tabelecleucel)

Pierre Fabre to Lead Launch and Commercialization Activities for EBVALLO In Europe Following Transfer of European Commission Marketing Authorization from Atara Biotherapeutics EBVALLO is the